Core Insights - The article highlights the growing interest in the "AI virtual cell" sector, driven by advancements in technology and data acquisition methods like single-cell sequencing, which have led to an explosion of multi-omics data [2][4]. Company Overview - Baiyao Technology recently completed a multi-million yuan angel round of financing, led by Fengrui Capital, with Shunxi Capital participating and Mingde Capital serving as the exclusive financial advisor [3]. - The founding team of Baiyao Technology released a pre-trained single-cell model in 2023, which has been iteratively improved to understand gene regulation and cellular state changes, simulating real cell behavior [3]. Technological Advancements - The single-cell model developed by Baiyao Technology integrates biological prior knowledge, enhancing learning directionality and producing results that align with biological logic [3]. - The model incorporates over 100 million single-cell gene expression data and conducts cross-species pre-training with human and mouse data, enabling the potential for effective translation of animal experiment data to predict human cell responses [3][4]. Industry Trends - The article notes that both the U.S. and China are actively promoting the use of foundational AI models for life simulation, with China's "14th Five-Year Plan" emphasizing the accelerated development of biotechnology and the establishment of major national scientific infrastructure in AI life sciences [4]. - Companies like Xaira Therapeutics and Asimov are already exploring applications of AI virtual cell models in areas such as tumor target discovery and stem cell differentiation [4]. Investment Perspectives - Investors view the virtual cell as a promising area, with the potential to significantly reduce trial-and-error costs and timelines in drug development and scientific research [6]. - Baiyao Technology is recognized for its deep expertise in virtual cell research, having developed multiple foundational and specialized models, and is collaborating with domestic and international pharmaceutical companies [6]. Future Outlook - The construction of AI virtual cells is described as a complex and resource-intensive endeavor, with potential investments reaching "hundreds of billions of dollars" to create comprehensive virtual cell models [5]. - The article emphasizes that the current technology is still in its early stages, but companies like Baiyao Technology are positioned to lead in high-quality data accumulation and algorithm iteration, potentially optimizing efficiency and costs in life sciences research and biopharmaceutical industries [5].

36氪获悉，AI虚拟细胞平台公司「百曜科技」近日完成数千万元天使轮融资，由峰瑞资本领投，顺禧 资本、百度风投跟投，明德资本担任独家财务顾问。 百曜科技创始团队早在2023年就发布了知识增强、跨物种、亿级数据量的单细胞预训练基础模型。随后 快速迭代并发布了首个基于图结构的单细胞预训练基础模型，让AI理解基因调控和内外环境下细胞状 态的变化的规律，从而模拟真实细胞行为。该系列研究成果曾作为封面文章发布于《Cell Research》以 及权威期刊《Advanced Science》和《NSR》上。 百曜科技对36氪表示，"团队构建的单细胞基础模型，采用预训练+微调路径，展现出优异的泛化能力 与广泛的下游应用潜力，为构建可产业落地的AI虚拟细胞平台奠定了技术基础。" 在训练过程中，该模型融合生物学先验知识，使学习更具方向性，输出结果更贴合生物学逻辑。此外， 模型首次整合超亿级单细胞基因表达数据，并联合人、小鼠两个物种进行跨物种预训练，从而学习共通 的生命规律，为后续将动物实验数据有效转化、预测人体细胞反应提供了可能。 近两三年来，在技术演进下，"AI虚拟细胞"成为备受关注的热门赛道。以单细胞测序为代表的数据获取 技 ...